99. Byrd TF, Horwitz MA. Interferon gamma-activated human monocytes
downregulate transferrin receptors and inhibit the intracellular
multiplication of Legionella pneumophila by limiting the availability of
iron. J Clin Invest 1989; 83: 1457–1465.
100. Mencacci A, Cenci E, Boelaert JR et al. Iron overload alters innate and T
helper cell responses to Candida albicans in mice. J Infect Dis 1997; 175:
1467–1476.
101. Nairz M, Theurl I, Ludwiczek S et al. The co-ordinated regulation of iron
homeostasis in murine macrophages limits the availability of iron for
intracellular Salmonella typhimurium. Cell Microbiol 2007; 9: 2126–2140.
102. Hoen B, Paul-Dauphin A, Hestin D et al. EPIBACDIAL: a multicenter
prospective study of risk factors for bacteremia in chronic hemodialysis
patients. J Am Soc Nephrol 1998; 9: 869–876.
103. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration
does not significantly increase the risk of bacteremia in chronic
hemodialysis patients. Clin Nephrol 2002; 57: 457–461.
104. Teehan GS, Bahdouch D, Ruthazer R et al. Iron storage indices: novel
predictors of bacteremia in hemodialysis patients initiating intravenous
iron therapy. Clin Infect Dis 2004; 38: 1090–1094.
105. Bernhardt WM, Wiesener MS, Scigalla P et al. Inhibition of prolyl
hydroxylases increases erythropoietin production in ESRD. J Am Soc
Nephrol 2010; 21: 2151–2156.
106. Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. First
of two parts–blood transfusion. N Engl J Med 1999; 340: 438–447.
107. MacLeod AM. The blood transfusion effect: clinical aspects. Immunol Lett
1991; 29: 123–126.
108. Shander A, Sazama K. Clinical consequences of iron overload from
chronic red blood cell transfusions, its diagnosis, and its management
by chelation therapy. Transfusion 2010; 50: 1144–1155.
109. Zhou YC, Cecka JM. Sensitization in renal transplantation. Clin Transpl
1991: 313–323.
110. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase
in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis
1999; 34: 125–134.
111. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on
cardiomyopathy, morbidity, and and mortality in end-stage renal
disease. Am J Kidney Dis 1996; 28: 53–61.
112. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis
patients: prevalence, incidence, prognosis and risk factors. Kidney Int
1995; 47:
884–890.
113. Rigatto C, Parfrey P, Foley R et al. Congestive heart failure in renal
transplant recipients: risk factors, outcomes, and relationship with
ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084–1090.
114. Collins AJ. Infl uence of target hemoglob in in dialysis patients on
morbidity and mortality. Kidney Int Suppl 2002: 44–48.
115. Ofsthun N, Labrecque J, Lacson E et al. The effects of higher hemoglobin
levels on mortality and hospitalization in hemodialysis patients. Kidney
Int 2003; 63: 1908–1914.
116. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes
in hemoglobin and administered erythropoiesis-stimulating agent and
survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181–1191.
117. Goodkin DA, Fuller DS, Robinson BM et al. Naturally occurring higher
hemoglobin concentration does not increase mortality among
hemodialysis patients. J Am Soc Nephrol 2011; 22: 358–365.
118. Besarab A, Bolton WK, Browne JK et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease
who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:
584–590.
119. Parfrey PS, Wish T. Quality of life in CKD patients treated with
erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55: 423–425.
120. Lietz K, Lao M, Paczek L et al. The impact of pretransplant erythropoietin
therapy on late outcomes of renal transplantation. Ann Transplant 2003;
8: 17–24.
121. Choukroun G, Kamar N, Dussol B et al. Correction of postkidney
transplant anemia reduces progression of allograft nephropathy. JAm
Soc Nephrol 2012; 23: 360–368.
122. Canadian Erythropoietin Study Group. Association between
recombinant human erythropoietin and quality of life and exercise
capacity of patients receiving haemodialysis. BMJ 1990; 300: 573–578.
123. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life
associated with recombinant human erythropoietin therapy for
predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25:
548–554.
124. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level
in patients with chronic kidney disease and anemia. N Engl J Med 2006;
355: 2071–2084.
125. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of
haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis
patients. Nephrol
Dial Transplant 2003; 18: 353–361.
126. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full
and partial anemia correction in incident hemodialysis patients without
symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180–2189.
127. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in
type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361 :
2019–2032.
128. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin
alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098.
129. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood
transfusions in hemodialysis patients without symptomatic cardiac
disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 2008;
3: 1669–1675.
130. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin
targets, and quality of life in healthy hemodialysis patients: a
randomized trial. Clin J Am Soc Nephrol 2009; 4: 726–733.
131. FDA presentation at Cardiovascular and Renal Drugs Advisory
Committee (CRDAC) meeting, 18 October 2010. http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
CardiovascularandRenalDrugsAdvisoryCommittee/UCM231978.pdf.
132. Lewis EF, Pfeffer MA, Feng A et al. Darbepoetin alfa impact on health
status in diabetes patients with kidney disease: a randomized trial. Clin J
Am Soc Nephrol 2011; 6: 845–855.
133. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesis-
stimulating agents in patients with chronic kidney disease. Ann Intern
Med 2010; 153: 23–33.
134. Gandra SR, Finkelstein FO, Bennett AV et al. Impact of erythropoiesis-
stimulating agents on energy and physical function in nondialysis CKD
patients with anemia: a systematic review. Am J Kidney Dis 2010; 55:
519–534.
135. Johansen KL, Finkelstein FO, Revicki DA et al. Systematic review and
meta-analysis of exercise tolerance and physical functioning in dialysis
patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis
2010; 55: 535–548.
136. Rizzo JD, Brouwers M, Hurley P et al. American Society of Clinical
Oncology/American Society of Hematology clinical practice guideline
update on the use of epoetin and darbepoetin in adult patients with
cancer. J Clin Oncol 2010; 28: 4996–5010.
137. Rizzo JD, Brouwers M, Hur ley P et al. American Society of Hematology/
American Society of Clinical Oncology clinical practice guideline update
on the use of epoetin and darbepoetin in adult patients with cancer.
Blood 2010; 116:
4045–4059.
138. Skali H, Parving HH, Parfrey PS et al. Stroke in patients with type 2
diabetes mellitus, chronic kidney disease, and anemia treated with
Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp
therapy (TREAT) experience. Circulation 2011; 124: 2903–2908.
139. Warady BA, Ho M. Morbidity and mortality in children with anemia at
initiation of dialysis. Pediatr Nephrol 2003; 18: 1055–1062.
140. Mitsnefes MM, Kimball TR, Kartal J et al. Progression of left ventricular
hypertrophy in children with early chronic kidney disease: 2-year follow-
up study. J Pediatr 2006; 149: 671–675.
141. Schaefer F. Cardiac disease in children with mild-to-moderate chronic
kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 292–297.
142. Morris KP, Sharp J, Watson S et al. Non-cardiac benefits of human
recombinant erythropoietin in end stage renal failure and anaemia. Arch
Dis Child 1993; 69: 580–586.
143. Gerson A, Hwang W, Fiorenza J et al. Anemia and health-related quality
of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004;
44: 1017–1023.
144. Staples AO, Wong CS, Smith JM et al. Anemia and risk of hospitalization
in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 48–56.
145. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and
outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363 :
1146–1155.
146. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients
treated with recombinant human erythropoietin. Kidney Int 2005; 68:
1337–1343.
147. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variabi lity and mortality
in ESRD. J Am Soc Nephrol 2007; 18: 3164–3170.
148. Eckardt KU, Kim J, Kronenberg F et al. Hemoglobin variability does not
predict mortality in European hemodialysis patients. J Am Soc Nephrol
2010; 21: 1765–1775.
149. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with
intravenous epoetin in patients receiving hemodialysis. Department of
Kidney International Supplements (2012) 2, 331–335 333
references